Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Decline in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) saw a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 44,811 shares, a decrease of 72.4% from the May 14th total of 162,618 shares. Approximately 3.9% of the company’s stock are sold short. Based on an average daily volume of 99,259 shares, the short-interest ratio is currently 0.5 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is currently owned by institutional investors and hedge funds.

Ernexa Therapeutics Trading Down 6.1%

Ernexa Therapeutics stock traded down $0.40 during mid-day trading on Friday, hitting $6.15. The company had a trading volume of 27,962 shares, compared to its average volume of 137,248. The stock’s 50 day moving average price is $7.48 and its two-hundred day moving average price is $16.24. Ernexa Therapeutics has a 12 month low of $3.18 and a 12 month high of $71.50. The company has a market capitalization of $7.20 million, a PE ratio of -0.23 and a beta of 2.49.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). Equities research analysts anticipate that Ernexa Therapeutics will post -18.02 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wall Street Zen cut Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Brookline Capital Markets assumed coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.